216 related articles for article (PubMed ID: 9215817)
1. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
[TBL] [Abstract][Full Text] [Related]
2. Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Cocconi G; Bisagni G; Ceci G; Bacchi M; Boni C; Brugia M; Carpi A; Di Costanzo F; Franciosi V; Gori S
J Clin Oncol; 1992 Jun; 10(6):984-9. PubMed ID: 1588379
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
[TBL] [Abstract][Full Text] [Related]
4. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
Rose C; Kamby C; Mouridsen HT; Andersson M; Bastholt L; Møller KA; Andersen J; Munkholm P; Dombernowsky P; Christensen IJ
Breast Cancer Res Treat; 2000 May; 61(2):103-10. PubMed ID: 10942095
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
Ingle JN; Green SJ; Ahmann DL; Long HJ; Edmonson JH; Rubin J; Chang MN; Creagan ET
J Clin Oncol; 1986 Jun; 4(6):958-64. PubMed ID: 3519885
[TBL] [Abstract][Full Text] [Related]
6. Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide.
Horton J; Knuiman M; Keller AM; Vogel H; Gale KE; Hahn RG; Rosenbluth RJ; Tormey DC
Cancer; 1987 Nov; 60(9):2137-40. PubMed ID: 3440224
[TBL] [Abstract][Full Text] [Related]
7. Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide.
Brufman G; Isacson R; Haim N; Gez E; Sulkes A
Oncology; 1994; 51(3):258-61. PubMed ID: 8196908
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
9. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185).
Cobau CD; Declercq K; Neuberg D; Ingle JN; Tormey DC
Cancer; 1996 Feb; 77(3):483-9. PubMed ID: 8630955
[TBL] [Abstract][Full Text] [Related]
11. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
Grem JL; Falkson G; Love RR; Tormey DC
Am J Clin Oncol; 1988 Oct; 11(5):528-34. PubMed ID: 3177253
[TBL] [Abstract][Full Text] [Related]
12. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association.
Muss HB; Case LD; Capizzi RL; Cooper MR; Cruz J; Jackson D; Richards F; Powell BL; Spurr CL; White D
J Clin Oncol; 1990 Nov; 8(11):1797-805. PubMed ID: 2230868
[TBL] [Abstract][Full Text] [Related]
13. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
Muss HB; Wells HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Powell BL
J Clin Oncol; 1988 Jul; 6(7):1098-106. PubMed ID: 3292710
[TBL] [Abstract][Full Text] [Related]
14. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Rose C; Kamby C; Mouridsen HT; Bastholt L; Brincker H; Skovgaard-Poulsen H; Andersen AP; Loft H; Dombernowsky P; Andersen KW
Breast Cancer Res Treat; 1986; 7 Suppl():S45-50. PubMed ID: 3527306
[TBL] [Abstract][Full Text] [Related]
15. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
J Clin Oncol; 2000 Apr; 18(7):1399-411. PubMed ID: 10735887
[TBL] [Abstract][Full Text] [Related]
16. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.
Goodwin JW; Green SJ; Moinpour CM; Bearden JD; Giguere JK; Jiang CS; Lippman SM; Martino S; Albain KS
J Clin Oncol; 2008 Apr; 26(10):1650-6. PubMed ID: 18375894
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
[TBL] [Abstract][Full Text] [Related]
18. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer.
Gennatas CS; Kalovidouris A; Paraskevas GA; Kouvaris J; Trichopoulos D; Papavasiliou C
Radiother Oncol; 1987 Jul; 9(3):217-20. PubMed ID: 3628857
[TBL] [Abstract][Full Text] [Related]
20. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
Thürlimann B; Paridaens R; Serin D; Bonneterre J; Roché H; Murray R; di Salle E; Lanzalone S; Zurlo MG; Piscitelli G
Eur J Cancer; 1997 Oct; 33(11):1767-73. PubMed ID: 9470830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
